It is very uncertain whether methotrexate + infliximab changes adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether methotrexate + infliximab changes serious adverse events (Schröder 2006) compared with infliximab alone (very low certainty).
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).
The review found no eligible studies for this question.
Infliximab 5 mg/kg and purine analogues showed no clear difference in withdrawals due to adverse events at week 26 compared with purine analogues alone (low certainty).
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).